Therapeutic siRNA: state of the art

B Hu, L Zhong, Y Weng, L Peng, Y Huang… - Signal transduction and …, 2020 - nature.com
ABSTRACT RNA interference (RNAi) is an ancient biological mechanism used to defend
against external invasion. It theoretically can silence any disease-related genes in a …

The current state and future directions of RNAi-based therapeutics

RL Setten, JJ Rossi, S Han - Nature reviews Drug discovery, 2019 - nature.com
The RNA interference (RNAi) pathway regulates mRNA stability and translation in nearly all
human cells. Small double-stranded RNA molecules can efficiently trigger RNAi silencing of …

RNA-targeting and gene editing therapies for transthyretin amyloidosis

A Aimo, V Castiglione, C Rapezzi, M Franzini… - Nature Reviews …, 2022 - nature.com
Transthyretin (TTR) is a tetrameric protein synthesized mostly by the liver and secreted into
the plasma. TTR molecules can misfold and form amyloid fibrils in the heart and peripheral …

Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug

AJ Debacker, J Voutila, M Catley, D Blakey, N Habib - Molecular Therapy, 2020 - cell.com
Targeted delivery of oligonucleotides to liver hepatocytes using N-acetylgalactosamine
(GalNAc) conjugates that bind to the asialoglycoprotein receptor has become a …

Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing

JK Nair, JLS Willoughby, A Chan… - Journal of the …, 2014 - ACS Publications
Conjugation of small interfering RNA (siRNA) to an asialoglycoprotein receptor ligand
derived from N-acetylgalactosamine (GalNAc) facilitates targeted delivery of the siRNA to …

Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates

DJ Foster, CR Brown, S Shaikh, C Trapp, MK Schlegel… - Molecular Therapy, 2018 - cell.com
Significant progress has been made in the advancement of RNAi therapeutics by combining
a synthetic triantennary N-acetylgalactosamine ligand targeting the asialoglycoprotein …

Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics

Y Huang - Molecular Therapy-Nucleic Acids, 2017 - cell.com
A main challenge in realizing the full potential of nucleic acid therapeutics is efficient
delivery of them into targeted tissues and cells. N-acetylgalactosamine (GalNAc) is a well …

[HTML][HTML] Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics

C Lorenzer, M Dirin, AM Winkler, V Baumann… - Journal of Controlled …, 2015 - Elsevier
Therapeutic gene silencing promises significant progress in pharmacotherapy, including
considerable expansion of the druggable target space and the possibility for treating orphan …

Therapeutic siRNA: state-of-the-art and future perspectives

M Friedrich, A Aigner - BioDrugs, 2022 - Springer
The highly specific induction of RNA interference-mediated gene knockdown, based on the
direct application of small interfering RNAs (siRNAs), opens novel avenues towards …

Clinical advances of siRNA therapeutics

B Hu, Y Weng, XH Xia, X Liang… - The journal of gene …, 2019 - Wiley Online Library
Small interfering RNA (siRNA) enables efficient target gene silencing by employing a RNA
interference (RNAi) mechanism, which can compromise gene expression and regulate gene …